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The epidemiology of heart failure has been described as an “epidemic” (1). Rates of 
hospitalisations for heart failure were rising in populations around the world. However, 
faster and more effective treatment for myocardial infarction and more effective treatment 
of other causes of heart failure such as hypertension has since led to a progressive fall in the 
incidence and first hospitalisation rate for heart failure in many countries(2–5). Multiple 
randomized controlled trials now document which pharmacological and device therapies 
improve morbidity and mortality in heart failure with reduced ejection fraction. As a result, 
we have seen progressive improvements in survival accompanying these reductions in 
hospitalization rates. In the current issue of the European Journal of Heart Failure, Schmidt 
et al (6) report the epidemiology of heart failure from an analysis of hospital discharge 
records in Denmark over a 30 year period. They confirm many of the trends described above 
by other investigators; rates of first hospitalisations for heart failure are falling and survival 
continues to improve. Confirming trends over time, and in different populations, is 
important to ensure that we continue to understand the natural history of heart failure and 
detect any new trends. But despite these reassuring trends, Schmidt et al (6) do report 
some data, consistent with other European and non-European data, that is worrying, and 
merits our attention. Namely the steady or increasing prevalence of heart failure and 
growing prevalence of co-morbidities.   
 
The trends in co-morbidities reflect the clinical experience of any specialist who cares for 
patients with heart failure. No longer is the typical patient with heart failure a man 
presenting a few months after a large anterior myocardial infarction they were lucky to 
survive. More commonly, it is an elderly man, or woman, with multiple co-morbidities. 
These co-morbidities present their own challenges in terms of treatment, for example 
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diabetes mellitus. The co-morbidities may influence the ability of the heart failure specialist 
to prescribe therapies that improve the prognosis of heart failure, the classic example being 
renal impairment and the inhibitors of the renin-angiotensin-aldosterone system. These co-
morbidities also have their own influence on prognosis (7).  One of the successes in the 
prevention of heart failure is the increasing age of the patients who present with heart 
failure. Median age at presentation to hospital for the first time increased by 2 years in the 
Danish cohort. The proportion of patients presenting at age 80 years or over increased by 
6% while the proportion of those in the 60-79 year old age group fell. However, with this 
increase in the age at presentation, there has been a corresponding increase in the burden 
of co-morbidities. Co-morbidities increase with age and complicate the treatment of heart 
failure. Although established and newer therapies for heart failure with reduced ejection 
fraction are consistently beneficial across the spectrum of age(8–10), the use of evidence 
based therapies may drop with advancing age and greater burden of co-morbidity(11). It is 
difficult therefore to predict what may happen at a population level when all of these trends 
and associations converge. Schmidt et al do present data on the common co-morbidities 
and trends in two of these are worthy of greater scrutiny; atrial fibrillation and diabetes.  
 
For instance the prevalence of type 2 diabetes mellitus (T2DM) is rising in patients with 
heart failure as it is in the general population. A diagnosis of T2DM increases the risk of 
death in patients with HF. While Schmidt et al (6) did find that the prevalence of T2DM 
increased year on year, the authors concede that the prevalence of T2DM was lower than 
other Western countries but similar to other patient groups in Denmark. The risk of death 
was higher in those with diabetes, as is to be expected from prior studies, but satisfyingly 
first hospitalisations for heart failure fell in this group. This might be considered unexpected 
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as recently there has been great concern that the treatments used to control blood glucose 
in T2DM may increase the risk of heart failure hospitalisation (12) and efforts have 
concentrated on ensuring new therapies do not cause heart failure. Therefore, despite 
many reasons to suspect that there may be unfavourable trends in those with diabetes, the 
opposite was reported. With recent evidence that new therapies for the treatment of 
diabetes can reduce heart failure hospitalisations (13) we hope that this trend may continue 
and it will be important to confirm this.  
 
While overall survival has improved, gains in survival have not been equally distributed 
amongst patients with different co-morbidities. The absolute and relative reductions in 
mortality were smaller in those with atrial fibrillation compared to other co-morbidities 
such as myocardial infarction. Recent meta-analysis of the betablocker trials conducted in 
heart failure have suggested that betablockers may only reduce mortality and morbidity in 
patients with heart failure who are in sinus rhythm (14). Certainly this would seem to fit 
with the trends in population level survival reported by Schmidt et al (6), this group is not 
experiencing the same gains as others. Those with T2DM have also not seen particularly 
large reductions in mortality. This again would fit with there being no therapies available 
during the study period that convincingly reduce morbidity and mortality in T2DM. So while 
the prognosis of HF has improved the prognosis of T2DM has not. This is of course, all 
speculation. Without population level data on prescribing rates we can only speculate on 
the myriad of potential interacting explanations for these trends. It will be important to 
continue to monitor these trends as newer therapies and data indicate that mortality can be 
altered by pharmacotherapy in patients with T2DM (13). What is however highlighted by 
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these data is the need to involve multiple specialists (diabetes, respiratory and renal 
experts) in the care of patients with heart failure. 
 
While there are worrying trends in individual co-morbidities, perhaps the greatest concern 
is the increase in the total burden of co-morbidities over time. The proportion of patients 
with one or more co-morbidity rose from 34 to 43%. Survival at 5 years in those with 2 or 
more co-morbidities was an appalling 22%, 50% had died within 1 year. As the population 
with heart failure ages, and the number of co-morbidities increase, these statistics should 
worry any heart failure specialist. Despite successes in the treatment of heart failure they 
highlight the truly terrible prognosis of patients when we look outside of the highly selected 
cohorts of patients recruited into randomised controlled trials. But is it fair to blame all of 
these statistics on the treatment of patients with multiple co-morbidities or is there another 
explanation? 
  
Schmidt et al (6) note that in common with many epidemiological datasets they did not 
have information on ejection fraction. This weakness is unfortunate, as it may explain why 
some these trends have been observed. Co-morbidities are common in those with heart 
failure with preserved ejection fraction (7). Could these trends simply reflect an increasing 
prevalence of heart failure with preserved ejection fraction? Without data on ejection 
fraction it is difficult to say. However, we might speculate that this may be the case. 
 
Finally, it is worth reflecting on the impact of registry based data such as these. Northern 
European countries such as Denmark have been at the forefront of the systematic collection 
of health data by public health care systems which cover the entire population and country. 
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The foresight of those who initiated these electronic systems is to be commended, as they 
continue to provide valuable epidemiological data. However, most population registries are 
from Northern Europe or North America and we have little information about heart failure 
from the rest of the world (15). Even within Europe the populations are heterogeneous. 
There are significant within and cross country variations and inequalities in the financing, 
organisation, access, delivery, quality and effectiveness of cardiac care in Europe(16). 
Therefore, secular trends in Denmark may not be applicable to many of the countries in 
Europe and even less so to other countries across the world.  What is clear is that registry 
based studies are going to become more common as health care systems adopt and 
integrate e-health technology (17). Through the integration of high quality registries on 
treatment of patients with outcome data such as hospitalisations and death registers, 
markers of the quality of care of patients can be examined, developed and subsequently 
improved (18).  
 
Although registries hold much promise, and their use is likely to change radically, we must 
be mindful of the trends that are demonstrated through their interrogation. The growing 
problem of co-morbidities is an issue that heart failure specialists will have to deal with. The 
scale and impact of this issue means that we cannot ignore it and we must incorporate it 
into the treatment of our patients if we are to improve the prognosis of patients with heart 
failure.  
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